#106249
#106250
Re: Farmas USA
#106251
Re: Farmas USA
#106252
Re: Farmas USA
#106253
Re: Farmas USA
#106254
Re: Farmas USA
HZNP
La presentación de diapositivas de la rueda de hoy
Y la transcripción completa:
#106255
Re: Farmas USA
CELG
Why the Celgene Damage May Be an Overreaction
A meeting with the FDA, to ascertain what additional information will be required to resubmit the NDA.
after the fact:
- Credit Suisse maintained its Outperform rating but lowered its target price to $129 from $130.
- SunTrust Robinson Humphrey downgraded it to Hold from Buy with a new $106 price target, down from $139.
- Stifel maintained its Buy rating but trimmed its target to $128 from $130.
- Robert W. Baird cut its price target to $92 from $101.
- BMO Capital markets cut the price target to $139 from $144.
- Guggenheim Securities cut its price target to $124 from $144.
- Leerink cut its price target to $123 from $135.
- Piper Jaffray cut its price target to $95 from $105.
- RBC Capital Markets cut its price target to $131 from $140.
#106256